

Caitlin A McIntyre

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5844423/publications.pdf>

Version: 2024-02-01

18
papers

213
citations

1163117

8
h-index

1058476

14
g-index

18
all docs

18
docs citations

18
times ranked

436
citing authors

#	ARTICLE	IF	CITATIONS
1	Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2020, 126, 3939-3949.	4.1	44
2	CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma. <i>Abdominal Radiology</i> , 2019, 44, 3148-3157.	2.1	37
3	Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors. <i>Hpb</i> , 2019, 21, 612-618.	0.3	34
4	Intraductal Papillary Mucinous Neoplasms: Have IAP Consensus Guidelines Changed our Approach?. <i>Annals of Surgery</i> , 2021, 274, e980-e987.	4.2	22
5	Perioperative Bundle to Reduce Surgical Site Infection after Pancreaticoduodenectomy: A Prospective Cohort Study. <i>Journal of the American College of Surgeons</i> , 2019, 228, 595-601.	0.5	14
6	Recurrence After Resection of Pancreatic Cancer: Can Radiomics Predict Patients at Greatest Risk of Liver Metastasis?. <i>Annals of Surgical Oncology</i> , 2022, 29, 4962-4974.	1.5	11
7	Detailed Analysis of Margin Positivity and the Site of Local Recurrence After Pancreaticoduodenectomy. <i>Annals of Surgical Oncology</i> , 2021, 28, 539-549.	1.5	9
8	Multimodal radiomics and cyst fluid inflammatory markers model to predict preoperative risk in intraductal papillary mucinous neoplasms. <i>Journal of Medical Imaging</i> , 2020, 7, 1.	1.5	8
9	Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2022, 125, 425-436.	1.7	6
10	Quantitative Computed Tomography Image Analysis to Predict Pancreatic Neuroendocrine Tumor Grade. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 679-694.	2.1	5
11	Multi-institutional Validation Study of Cyst Fluid Protein Biomarkers in Patients With Cystic Lesions of the Pancreas. <i>Annals of Surgery</i> , 2022, 276, e129-e132.	4.2	5
12	Toward an Optimized Staging System for Pancreatic Ductal Adenocarcinoma: A Clinically Interpretable, Artificial Intelligence-Based Model. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 1220-1231.	2.1	5
13	Hepatocellular carcinoma in patients with no identifiable risk factors. <i>Hpb</i> , 2021, 23, 118-126.	0.3	4
14	Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery. <i>Abdominal Radiology</i> , 2021, 46, 1607-1617.	2.1	4
15	Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Treatment Does Not Predict Pathological Response and Survival in Resectable Pancreatic Ductal Adenocarcinoma. <i>American Surgeon</i> , 2022, 88, 1153-1158.	0.8	4
16	Differentiation of mucinous cysts and simple cysts of the liver using preoperative imaging. <i>Abdominal Radiology</i> , 2022, 47, 1333-1340.	2.1	1
17	How Long Should Patients with Cystic Lesions of the Pancreas Be Followed?. <i>Advances in Surgery</i> , 2018, 52, 223-233.	1.3	0
18	ASO Visual Abstract: Recurrence After Resection of Pancreatic Cancer – Can Radiomics Predict Patients at Greatest Risk of Liver Metastasis?. <i>Annals of Surgical Oncology</i> , 2022, , .	1.5	0